Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

88.71
+1.782.05%
Pre-market: 89.150.4400+0.50%06:08 EDT
Volume:902.46K
Turnover:79.43M
Market Cap:7.82B
PE:-44.14
High:88.72
Open:85.56
Low:85.26
Close:86.93
52wk High:110.18
52wk Low:14.51
Shares:88.17M
Float Shares:80.98M
Volume Ratio:0.82
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:8.19
PE(LYR):-44.91

Loading ...

Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares

Reuters
·
Aug 11

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

MT Newswires Live
·
Aug 10

Spyre Therapeutics Announces Launch of Spy772 Program and Initiation of Phase 2 Skylight Trial in Hidradenitis Suppurativa

THOMSON REUTERS
·
Aug 10

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

GlobeNewswire
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 08

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Aug 08

Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million

Reuters
·
Aug 06

Spyre Therapeutics Inc : Jefferies Raises Target Price to $122 from $98

THOMSON REUTERS
·
Aug 05

Spyre Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Reuters
·
Aug 05

Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 05

Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim

TIPRANKS
·
Jul 25

Movement Alert|Spyre Therapeutics Rises 11.41% in Regular Trading, Trading at $104.42

Market Focus
·
Jul 15

Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding?

Simply Wall St.
·
Jul 10

Movement Alert|Spyre Therapeutics Rises 5.02% in Regular Trading, Trading at $93.51

Market Focus
·
Jul 08

Spyre Therapeutics CEO Cameron Turtle Sells Common Shares Worth $1.32 Million

Reuters
·
Jul 03

Spyre Therapeutics Grants Inducement Equity Awards of 58,843 Stock Options, 2,134 Rsus to New Hires

Reuters
·
Jul 03

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Jul 03

Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative

Simply Wall St.
·
Jul 02

Spyre Therapeutics CFO Scott Burrows Disposes of Common Shares Worth $1.31 Million

Reuters
·
Jun 27